Target Name: LYPD8
NCBI ID: G646627
Other Name(s): LY6/PLAUR domain containing 8, transcript variant 1 | Uncharacterized protein UNQ511/PRO1026 | Ly6/PLAUR domain-containing protein 8 preproprotein | LY6/PLAUR domain containing 8 | LYPD8 variant 1 | LYPD8_HUMAN | phospholipase inhibitor | Ly6/PLAUR domain-containing protein 8

LYPD8: A Potential Drug Target and Biomarker

LYPD8, also known as LYP-PLAUR1, is a gene located on chromosome 6p21.3 that encodes for a protein containing 216 amino acids, which is expressed in various tissues and cell types. The protein is composed of two distinct domains, LYP domain and PLAUR domain. The LYP domain is a zinc finger protein that is known to play a role in various cellular processes, including cell signaling, DNA replication, and metabolism. The PLAUR domain is a protein domain that contains a unique array of conserved amino acids that are involved in protein-protein interactions and may be involved in the regulation of cellular processes.

Recent studies have identified LYPD8 as a potential drug target and biomarker. The LYP domain has been shown to play a role in various cellular processes, including cell signaling, which may be relevant to the development of drug targets. Additionally, the PLAUR domain has been shown to be involved in protein-protein interactions, which may be relevant to the regulation of cellular processes that are affected by drug treatments.

Domain Structure and Function

The LYP domain is a zinc finger protein that is composed of five conserved amino acids: LYS, LYS, LYT, LYE, and LYF. The LYP domain is responsible for the protein's unique structure and function. It is involved in the regulation of various cellular processes, including cell signaling, DNA replication, and metabolism.

The PLAUR domain is a protein domain that is composed of 14 conserved amino acids: AQE, AQF, AQG, AQH, AQI, AQJ, AQK, AQL, AQM, AQN, AQO, AQP, AQR, AQS, AQT, AQU, AQV, AQW, AQX, and AQY. The PLAUR domain is involved in the regulation of cellular processes, including the regulation of protein-protein interactions and the regulation of cellular signaling pathways.

LYPD8 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and metabolism. For example, LYPD8 has been shown to be involved in the regulation of cell signaling pathways, including the regulation of the T-cell receptor signaling pathway. Additionally, LYPD8 has been shown to be involved in the regulation of DNA replication, as a study found that LYPD8 was expressed in human leukemia cells and was shown to play a role in the regulation of DNA replication.

Furthermore, LYPD8 has also been shown to be involved in the regulation of metabolism, as a study found that LYPD8 was expressed in human tissues and was shown to play a role in the regulation of metabolism.

Potential Drug Target

The LYP domain is known to play a role in various cellular processes, including cell signaling, which may make it a potential drug target. The LYP domain has been shown to interact with various protein partners, including Src, Fyn, andFAK. Therefore, drugs that target these protein partners may be effective in blocking the activity of LYP domain and potentially inhibiting the function of LYPD8.

In addition, the PLAUR domain has also been shown to be involved in the regulation of cellular processes, including the regulation of protein-protein interactions and the regulation of cellular signaling pathways. Therefore, drugs that target protein-protein interactions or signaling pathways may be effective in inhibiting the activity of LYPD8 and potentially targeting the regulation of cellular processes.

Biomarker

The LYPD8 gene has been shown to encode a protein that is involved in various cellular processes, including cell signaling, DNA replication, and metabolism. Therefore, the LYPD8 gene and protein may be useful as a biomarker for the diagnosis and monitoring of various diseases, including cancer, cardiovascular disease, and metabolic disorders.

In addition, the LYPD8 gene and protein may be useful as a biomarker for assessing the effectiveness of various therapeutic treatments. For example, drugs that target the LYP domain or PLAUR domain may be effective in treating various diseases, including cancer, cardiovascular disease, and metabolic disorders.

Conclusion

LYPD8 is a gene located on chromosome 6p21.3 that encodes for a protein containing 216 amino acids. The LYP domain is responsible for the protein's unique structure and function, including the regulation of various cellular processes, including cell signaling, DNA replication, and metabolism. The PLAUR domain is involved in the regulation of cellular processes, including the regulation of protein-protein interactions and the regulation of cellular signaling pathways.

Recent studies have identified LYPD8 as a potential drug target and biomarker. The LYP domain has been shown to play a role in various cellular processes, including cell signaling, which may be relevant to the development of drug targets. Additionally, the PLAUR domain has been shown to be involved in the regulation of cellular processes, which may be relevant to the regulation of cellular signaling pathways.

Furthermore, LYPD8 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and metabolism. Therefore, the LYPD8 gene and protein may be useful as a biomarker for the diagnosis and monitoring of various diseases, including cancer, cardiovascular disease, and metabolic disorders. Additionally, the LYPD8 gene and protein may be useful as a biomarker for assessing the effectiveness of various therapeutic treatments.

Despite the potential benefits of targeting LYPD8, further research is needed to fully understand its role in cellular processes and its potential as a drug target and biomarker.

Protein Name: LY6/PLAUR Domain Containing 8

Functions: Secreted protein specifically required to prevent invasion of Gram-negative bacteria in the inner mucus layer of the colon epithelium, a portion of the large intestine which is free of commensal microbiota. Prevents invasion of flagellated microbiota by binding to the flagellum of bacteria, such as P.mirabilis, thereby inhibiting bacterial motility in the intestinal lumen. Segregation of intestinal bacteria and epithelial cells in the colon is required to preserve intestinal homeostasis

More Common Targets

LYPLA1 | LYPLA2 | LYPLA2P1 | LYPLA2P2 | LYPLAL1 | LYPLAL1-AS1 | LYRM1 | LYRM2 | LYRM4 | LYRM4-AS1 | LYRM7 | LYRM9 | LYSET | Lysine-Specific Demethylase 3 | Lysine-specific demethylase 5 | LYSMD1 | LYSMD2 | LYSMD3 | LYSMD4 | Lysophospholipid (edg) Receptors | LYST | Lysyl Oxidase Homolog | LYVE1 | LYZ | LYZL1 | LYZL2 | LYZL4 | LYZL6 | LZIC | LZTFL1 | LZTR1 | LZTS1 | LZTS1-AS1 | LZTS2 | LZTS3 | m-Calpain | M1AP | M6PR | MAB21L1 | MAB21L2 | MAB21L3 | MAB21L4 | MACC1 | MACC1-DT | MACF1 | MACIR | MACO1 | MACORIS | MACROD1 | MACROD2 | MACROD2-AS1 | MACROH2A1 | MACROH2A2 | MAD1L1 | MAD2L1 | MAD2L1BP | MAD2L2 | MADCAM1 | MADD | MAEA | MAEL | MAF | MAF1 | MAFA | MAFA-AS1 | MAFB | MAFF | MAFG | MAFIP | MAFK | MAFTRR | MAG | MAGEA1 | MAGEA10 | MAGEA11 | MAGEA12 | MAGEA13P | MAGEA2 | MAGEA2B | MAGEA3 | MAGEA4 | MAGEA5P | MAGEA6 | MAGEA7P | MAGEA8 | MAGEA9 | MAGEA9B | MAGEB1 | MAGEB10 | MAGEB16 | MAGEB17 | MAGEB18 | MAGEB2 | MAGEB3 | MAGEB4 | MAGEB5 | MAGEB6 | MAGEB6B | MAGEC1 | MAGEC2